Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
148 hedge funds and large institutions have $387M invested in Intercept Pharmaceuticals, Inc. in 2022 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 20 closing their positions.
44% more call options, than puts
Call options by funds: $21M | Put options by funds: $14.6M
5% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 20
1% more funds holding
Funds holding: 147 → 148 (+1)
3% less capital invested
Capital invested by funds: $400M → $387M (-$13.3M)
4% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$7.4M |
| 2 |
BlackRock
New York
|
+$6.63M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.54M |
| 4 |
Morgan Stanley
New York
|
+$5.84M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
+$4.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$17.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.86M |
| 3 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$2.98M |
| 4 |
Citigroup
New York
|
-$2.86M |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$2.75M |
ICPT Hedge Fund Activity: Q1 2022 in Review
148 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2022, worth a combined $387M — down 3.3% from $400M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ICPT positions and 20 closed out — a net gain of 1 holder — while 47 added to existing stakes and 49 trimmed.
The largest buyer was Eventide Asset Management, adding an estimated $7.4M. The largest seller was Adage Capital Partners, cutting an estimated $17.7M.
- 148 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2022, up from 147 in Q4 2021.
- Funds reported $387M of Intercept Pharmaceuticals, Inc. stock for Q1 2022, down 3.3% quarter-over-quarter.
- 21 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2022 and 20 closed out, a net change of +1 holder.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2022 was Eventide Asset Management, an estimated $7.4M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2022 was Adage Capital Partners, an estimated $17.7M sold.
Based on aggregated 13F filings for Q1 2022.